| Page 5 | Kisaco Research
 

Michaela Tolman

Commercial Development Lead for Inflammation & Immunology
Pfizer

Michaela Tolman

Commercial Development Lead for Inflammation & Immunology
Pfizer

Michaela Tolman

Commercial Development Lead for Inflammation & Immunology
Pfizer

As cross-border patent disputes expand, companies now face parallel proceedings in the UK, the UPC, the US, and Asia. From Unwired Planet v. Huawei to Panasonic v. OPPO, courts are asserting global influence over licensing, validity, and enforcement. This session explores how strategic forum selection and procedural divergence are reshaping litigation outcomes and global IP strategy.

• Compare how the UK, UPC, US, and German courts approach jurisdiction, declaratory relief, and parallel enforcement.
• Examine how anti-suit injunctions, interim measures, and case sequencing are used to influence settlement leverage.
• Review recent cross-border disputes, including Edwards Lifesciences v. Meril Life Sciences and Apple v. Masimo, to identify emerging litigation patterns across sectors.

Author:

Tom Brown

Senior Managing Legal Director, Head of Intellectual Property Litigation
Dell

Tom Brown

Senior Managing Legal Director, Head of Intellectual Property Litigation
Dell
 

Laura Shaughnessy

Development Strategy Lead
UCB

Laura Shaughnessy

Development Strategy Lead
UCB

Laura Shaughnessy

Development Strategy Lead
UCB
 

Clare Brem

CEO
Brem Foundation

Clare Brem

CEO
Brem Foundation

Clare Brem

CEO
Brem Foundation
 

Mary Dinnean

Director, Enterprise Strategic Initiatives
Elevance Health

Mary Dinnean

Director, Enterprise Strategic Initiatives
Elevance Health

Mary Dinnean

Director, Enterprise Strategic Initiatives
Elevance Health
 

Kristine Burke

CEO
True Health Center for Precision Medicine

Kristine Burke

CEO
True Health Center for Precision Medicine

Kristine Burke

CEO
True Health Center for Precision Medicine
 

Laura Herrera Scott

Chief Medical Officer
CareFirst BlueCross Blue Shield

Laura Herrera Scott, MD, is the Vice President and Chief Medical Officer (CMO) of CareFirst BlueCross BlueShield (CareFirst), one of the nation’s largest not-for-profit healthcare organizations. In this role, Dr. Herrera Scott leads CareFirst’s physician, inpatient management and healthcare policy teams, supporting efforts to achieve excellence in healthcare affordability, quality and accessibility through innovative initiatives to improve the health of CareFirst’s members and the communities it serves.

Laura Herrera Scott

Chief Medical Officer
CareFirst BlueCross Blue Shield

Laura Herrera Scott

Chief Medical Officer
CareFirst BlueCross Blue Shield

Laura Herrera Scott, MD, is the Vice President and Chief Medical Officer (CMO) of CareFirst BlueCross BlueShield (CareFirst), one of the nation’s largest not-for-profit healthcare organizations. In this role, Dr. Herrera Scott leads CareFirst’s physician, inpatient management and healthcare policy teams, supporting efforts to achieve excellence in healthcare affordability, quality and accessibility through innovative initiatives to improve the health of CareFirst’s members and the communities it serves.
Dr. Herrera Scott brings more than 20 years of clinical and strategic leadership experience across the healthcare industry. Most recently, she served as Secretary of the Maryland Department of Health, where she led several large-scale initiatives, including maintaining coverage for more than 1.6 million Marylanders during the post-pandemic Medicaid redetermination process and advancing legislation to protect women’s health and improve healthcare access statewide.

 

Jennesa Atherton

Head of Clinical Affairs
Sword Health

Jennesa Atherton

Head of Clinical Affairs
Sword Health

Jennesa Atherton

Head of Clinical Affairs
Sword Health
 

Richard Meiklejohn

Program Manager
Lahey Innovation Hub

Richard Meiklejohn

Program Manager
Lahey Innovation Hub

Richard Meiklejohn

Program Manager
Lahey Innovation Hub